R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Mark A. Dickson,Manish A. Shah,Dana E. Rathkopf,Archie Tse,Richard D. Carvajal,Nian Wu,Robert A. Lefkowitz,Mithat Gonen,Lauren M. Cane,H. Dials,Gary K. Schwartz +10 more
TL;DR: Concentrations of flavopiridol that enhance the effects of FOLFIRI can be achieved and includes prolonged stable disease in patients with irinotecan-refractory colorectal cancer.
Journal ArticleDOI
Ipilimumab-induced colitis on FDG PET/CT.
TL;DR: Physicians interpreting FDG PET/CT examinations of patients treated with ipilimumab should be aware of these FDG-avid immune-mediated toxicities.
Journal ArticleDOI
Dropped head syndrome: Report of three cases during treatment with a MEK inhibitor
TL;DR: Selumetinib (AZD6244, ARRY-142886), a selective non-ATP competitive small-molecule inhibitor of MEK1/2,1 has been used in the regulation of many cellular processes.
Journal ArticleDOI
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
Funda Meric-Bernstam,Nizar M. Tannir,James W. Mier,Angela DeMichele,Melinda L. Telli,Alice C. Fan,Pamela N. Munster,Richard D. Carvajal,Keith W. Orford,Mark K. Bennett,Othon Iliopoulos,Taofeek K. Owonikoko,Manish R. Patel,Rana R. McKay,Jeffrey R. Infante,Martin H. Voss,James J. Harding +16 more
TL;DR: CB-839 is a selective inhibitor of GLS, a key enzyme in the utilization of glutamine by many cancer cells, and has broad activity in preclinical models, including RCC.
Journal ArticleDOI
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
TL;DR: This analysis of BRAFi/MEKi combinations for BRAF-mutant melanoma, while limited as not a direct head-to-head clinical trial, highlights the differences in tolerability and efficacy that may be useful for therapeutic decision making.